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Abstract
Background—Radiofrequency ablation (RFA) is effective for treating Barrett's esophagus (BE)
but often involves multiple endoscopy sessions over several months to achieve complete response.
Objective—Identify structural markers using three-dimensional optical coherence tomography
(3D-OCT) that correlate with treatment response.
Design—Cross-sectional.
Setting—Single teaching hospital.
Patients—Thirty-two male and one female Caucasians with short-segment BE (<3cm)
undergoing RFA treatment.
Interventions—Patients were treated with focal RFA and 3D-OCT was performed at the
gastroesophageal junction before and immediately after the RFA treatment. Patients were re-
examined with standard endoscopy 6-8 weeks later and biopsied to rule out BE if not visibly
evident.
Main outcome measurement—The thickness of BE epithelium before RFA and the presence
of residual-gland-like structures immediately after RFA were determined using 3D-OCT. The
presence of BE at follow-up was assessed endoscopically.
Results—BE mucosa was significantly thinner in patients who achieved complete eradication of
intestinal metaplasia (CE-IM) than in patients who did not achieve CE-IM at follow-up
[257±60μm vs. 403±86μm, p<0.0001]. A threshold thickness of 333μm derived from receiver-
operator characteristics corresponds to a 92.3% sensitivity, 85% specificity and 87.9% accuracy in
predicting the presence of BE at follow-up. The presence of OCT-visible glands immediately after
RFA also correlated with the presence residual BE at follow-up (83.3% Sensitivity, 95%
specificity, and 90.6% accuracy).
Limitations—Single center, cross sectional study and only patients with short-segment BE were
examined.
Conclusions—3D-OCT assessment of BE thickness and residual glands during RFA sessions
correlated with treatment response. 3D-OCT may predict response to RFA or make real-time RFA
retreatment decisions in the future.
Keywords
Optical Coherence Tomography; Optical Biopsy; Barrett's Esophagus; Radiofrequency Ablation;
Epithelial depth
Introduction
Radiofrequency ablation (RFA) is an emerging endoscopic therapy for treating Barrett's
esophagus (BE).1-5 Utilizing electrode arrays, RFA catheters deliver radiofrequency energy
to the surface of esophageal tissues to ablate BE with a low stricture rate.6, 7 Recent studies
have shown that at one year follow-up from the initial RFA treatment, complete eradication
of dysplasia (CE-D) was achieved in 90.5% of patients with low grade dysplasia (LGD) and
in 81% of patients with high grade dysplasia (HGD).4 At two year follow-up, CE-D was
achieved in 98% and 93% of patients with LGD and HGD, respectively.8 Complete
eradication of intestinal metaplasia (CE-IM) was achieved in 93% of the patients with
dysplasia after two years8 and in 92% of patients with non-dysplastic BE (NDBE) at 5-year
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follow-up.9 However, recurrence of intestinal metaplasia (IM) was observed in 13%8 and
even 25.9%10 of patients at 1 year after CE-IM was achieved. It is unclear what risk factors
are associated with the recurrence of IM.
Repeated RFA treatments are generally required to achieve complete eradication of aberrant
tissues.11-13 On average, CE-IM was achieved after 3.4 RFA sessions for patients with
NDBE9 and over 3.5 sessions for patients with dysplasia.4, 8 Considering the follow up time
between RFA procedures (usually 6-8 weeks), the entire treatment process can easily span
half a year or longer. In addition, the cost to achieve complete eradication mounts with each
esophagogastroduodenoscopy (EGD) and RFA procedure, and has tempered the enthusiasm
to treat all NDBE using RFA.14, 15 Therefore, improving the effectiveness of each RFA
procedure would reduce the number of treatment sessions, improve cost effectiveness,
reduce patient anxiety and make this therapy available to a wider patient population.
Optical coherence tomography (OCT) is a volumetric imaging technique that generates
cross-sectional and 3D images of tissue microstructures with micron scale resolution.16
Endoscopic OCT techniques have been developed to image the human gastrointestinal (GI)
tract with over 1 mm imaging depth.17-26 Two-dimensional OCT has been used to evaluate
specialized intestinal metaplasia, dysplasia, and adenocarcinoma in the esophagus and has
achieved a high sensitivity and specificity to differentiate different pathologies.22, 27
Recently, endoscopic 3D-OCT has become possible due to dramatic increases in imaging
speed.23-26 3D-OCT provides a powerful combination of high resolution, large field of view,
and rapid data acquisition. 3D-OCT has been used to image patients with upper and lower
GI diseases.23, 26 Recent studies demonstrated that 3D-OCT can identify buried glands
before and after CE-IM from RFA treatment.23, 28 The objective of this investigation was to
identify possible structural markers that predict RFA treatment response using endoscopic
3D-OCT.
Methods
Patient Enrollment and Study Protocol
This study was conducted at the Veterans Affairs Boston Healthcare System (VABHS),
Jamaica Plain Campus over the past 2 years. The study protocol was approved by the
VABHS, Harvard Medical School and Massachusetts Institute of Technology. Patients were
diagnosed with standard white light endoscopy and the length of visible BE was recorded
based on the Prague C&M criteria.29 Thirty-three patients with short-segment BE (<3 cm),
including one female, were recruited for this study. The study also included patients who
initially presented with long segment BE that were reduced to less than 3 cm segment by
prior circumferential RFA treatment using the BARRX Halo360™ catheter. Informed
consent was obtained from each patient. Only patients with short-segment BE were imaged
in order to ensure consistent OCT imaging catheter placement at the gastroesophageal
junction (GEJ) and ascertaining presence of BE, thickness, and residual glands relative to
the GEJ within the OCT pullback image. This study focused on patients receiving ablation
with the Halo90™ catheter. For each RFA treatment, the patient received two sets of
ablations using the BARRX Halo90™ catheter (300 Watts at 12 J/cm2 for each set of
ablations), with rigorous scraping to remove desquamated epithelium between the two
ablations, per standard protocol set by the manufacture. Patients with circumferential short-
segment BE were also treated using Halo90™ catheter in order to maintain consistent
procedure and ablation energy level. After the RFA, patients received a proton pump
inhibitor (PPI), i.e., 40 mg of esomeprazole or omeprazole bid. At 6-8 weeks follow-up, the
presence of residual BE was evaluated using white light endoscopy and narrow band
imaging (NBI), as well as random 4-quandrant pinch biopsies. If no visible BE was
observed endoscopically and no IM was found from biopsies at the GEJ the patient was
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classified as CE-IM. There were 13 patient in the CE-IM Group and 20 patients in the Non-
CE-IM Group in this study.
Endoscopic 3D-OCT Imaging
A prototype endoscopic 3D-OCT system,25, 30 developed by LightLab Imaging - St Jude
Medical (Westford, Massachusetts, USA), was used for this study. The system had a lateral
resolution of 15 μm, an axial resolution of 5 μm and imaging depth of ∼2 mm in tissue. 3D-
OCT imaging was performed with the OCT catheter introduced through the biopsy channel
of the endoscope (GIF Q180; Olympus, Tokyo, Japan), enabling simultaneous video
endoscopy. Volumetric OCT data was acquired at 60,000 axial lines per second and 60
frames per second. The imaging catheter scanned a helical pull back pattern with an 8 mm
circumference and 20 mm pullback length within 20 seconds. The endoscope was at the
neutral position with the imaging catheter placed at 6 o'clock in the endoscopic field. The
imaging catheter was in contact with the esophagus and the pull back imaging spanned the
GEJ. The esophagus was deflated and naturally wrapped around the OCT catheter during
imaging acquisition to maintain a consistent catheter contact for all patients. Multiple 3D-
OCT datasets were acquired at the GEJ before and immediately after the RFA treatment.
Image Analysis
Each 3D-OCT data set was reviewed and analyzed using 3D rendering software (Amira,
Visage Imaging, Inc.). The BE epithelium thickness was measured from cross-sectional
OCT images obtained prior to the RFA treatment. As indicated in Figure 1, the BE thickness
was measured as the vertical distance from the top of the lamina propria (LP) / muscularis
mucosa (MM) layer to the surface of the BE epithelium at the center position where the
OCT catheter had the best contact with the esophagus. Multiple BE thickness measurements
were obtained from each 3D data set every 1 mm along the entire BE length. The average
and maximum BE thickness were recorded for each patient for statistical comparison
between the CE-IM and Non-CE-IM groups.
In addition, two types of residual glandular structures were observed by reviewing 3D-OCT
images obtained immediately after the second RFA. The first type of glandular structure was
unburned BE epithelium that was likely missed by RFA and showed similar epithelial
structure as that of regular BE. The second type of glandular structure consisted of
hyposcattering glandular structures above the LP/MM layer at the RFA treatment site,
representing residual glands. The presence or absence of these residual glands was recorded
for each patient.
Statistical Analysis
The primary study outcome was to determine the accuracy of using BE thickness measured
with OCT prior to RFA to predict the treatment response (presence or absence of
endoscopically visible residual BE at follow-up). A Student's t-test was used to compare the
average and maximum BE thickness from the CE-IM and Non-CE-IM groups. To evaluate
whether BE thickness can be used to predict the RFA treatment response, receiver operator
characteristic (ROC) curves were plotted by using a discrimination threshold ranging from
100 μm to 800 μm for average and maximum BE thickness, respectively. A decision
threshold was determined from the ROC curves to achieve maximum overall accuracy.
Sensitivity, specificity, positive predicting value (PPV), negative predicting value (NPV)
and accuracy of the prediction was then calculated.
The secondary study outcome was to evaluate the correlation between the presence or
absence of residual glands on OCT imaging immediately after RFA versus RFA treatment
response assessed endoscopically on follow up. In addition, we also evaluated the
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correlation between the BE thickness prior to RFA versus the presence or absence of
residual glands immediately after RFA. The sensitivity, specificity, PPV, NPV and the
accuracy were calculated.
All statistical analyses were performed using MATALB software (Mathworks Inc.). All tests
were two-sided and a p value of < 0.05 was considered statistically significant.
Results
Table 1 lists demographic information of the patients enrolled in this study. The average age
for the CE-IM and Non-CE-IM groups were comparable (p=0.86). The CE-IM group
consisted of 13 patients (4 patients had BE without dysplasia, 2 BE with low-grade dysplasia
and 7 BE with high-grade dysplasia at presentation). The Non-CE-IM group consisted of 20
patients (10 patients had BE without dysplasia, 4 BE with low-grade dysplasia and 6 BE
with high-grade dysplasia at presentation). Patients in the Non-CE-IM group are presumed
to eventually have a treatment response with additional RFA treatments and convert to the
CE-IM group and investigation of this group is ongoing. The number of prior RFA
treatments and the length of BE was not statistically different between the two groups. There
were no adverse events after RFA treatment.
Figure 1A shows an example endoscopic image of the GEJ before applying focal RFA
treatment. 3D-OCT imaging was performed at the GEJ over the area of BE (pink colored).
Figure 1B shows a representative cross-sectional OCT image obtained at the GEJ prior to
the RFA treatment, together with histology obtained from the same site (Figure 1C). The
thickness of the BE epithelium was measured from the OCT image as distance between the
BE surface to the top of the LP / MM layer.
Figure 2A shows an example endoscopic image of the GEJ immediately after focal RFA
treatment with scraping to remove desquamated epithelium between first and second RFA
application. The RFA treated area was covered with blood and burned tissue, making it
difficult to identify residual BE patches on white light endoscopy or NBI. Figure 2B shows a
representative cross-sectional OCT image obtained immediately after RFA. Similar
epithelium structure was observed compared to Figure 1B, indicating the presence of
residual BE that was missed by the RFA treatment. A video of cross-sectional OCT images
scanning through the unburned BE area is provided in the Supplemental Materials (Video
S1). Another type of residual glandular structure usually can be observed after insufficient
power delivery on the tissue, leading to hyposcattering features above the LP/MM layer at
the RFA treated site in OCT images. Figure 2C shows residual glands (red arrows) above
the MM layer, suggesting these glands were not effectively removed by the RFA treatment.
A biopsy was taken from the same site immediately after the OCT imaging and confirmed
the presence of residual BE glands immediately after the RFA treatment (Figure 2D). A
video of cross-sectional OCT images scanning through these residual BE glands is provided
in the Supplemental Materials (Video S2). Figure 2E shows a representative OCT image
demonstrating effective RFA treatment, where the MM layer was on top of the tissue surface
with no epithelial structures above it. A video of cross-sectional OCT images scanning
through the effectively treated area is provided in the Supplemental Materials (Video S3).
The BE thickness measured with OCT prior to RFA was found to be a predictor of the RFA
treatment response. Both the average and maximum BE thickness prior to RFA were
significantly thinner for the CE-IM group compared to the Non-CE-IM group [Average BE
thickness, 257±60 μm versus 403±86 μm, p<0.0001; Maximum BE thickness, 293±64 μm
versus 471±107 μm, p<0.0001]. The scatter plot in Figure 3A shows the difference between
the average BE thickness for the two groups. Figure 3B shows ROC curves using average
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and maximum BE thickness to predict RFA treatment response. The area-under-the-curve
(AUC) was 0.942 (p<0.001) and 0.934 (p<0.001) using the average and maximum BE
thickness, respectively. An average BE thickness of 333 μm was determined from the ROC
curve to achieve the best prediction accuracy. Using this decision threshold, a sensitivity of
92.3% (12/13), specificity of 85% (17/20), PPV of 80%, NPV of 94.4% and an accuracy of
87.9% (29/33) was obtained for predicting treatment response evaluated by the presence or
absence of endoscopically visible residual BE at follow-up visit using the average BE
thickness measured with OCT prior to the RFA treatment (Table 2). Considering only the
patients with dysplastic BE (19/33), a sensitivity of 100% (9/9), specificity of 90% (9/10),
PPV of 90%, NPV of 100% and an accuracy of 94.7% (18/19) was obtained for predicting
treatment response evaluated by the presence or absence of endoscopically visible residual
BE at the follow-up visit using the average BE thickness measured with OCT prior to RFA
treatment. The BE thickness measured with OCT was not correlated with the length of the
BE (p=0.88) or the number of prior RFA treatments (p=0.24).
A BE thickness of over 333 μm was also found to correlate with the presence of residual
glands immediately after RFA [Table 3, sensitivity: 91.7% (11/12), specificity: 85% (17/20),
PPV: 78.6%, NPV: 94.4%, and accuracy: 87.5% (28/32)]. Note that one subject was
excluded from this analysis due to the lack of OCT images immediately after RFA. Finally,
the presence of residual glands observed with OCT immediately after RFA was found to be
another predictor of the RFA treatment response (Table 4). Sensitivity of 83.3% (10/12),
specificity of 95% (19/20), PPV of 90.9%, NPV of 90.5% and an accuracy of 90.6% (29/32)
was achieved when using the presence of residual glands visible on OCT immediately after
RFA to predict the presence of endoscopically visible residual BE at follow-up.
Discussion
While endoscopic 3D-OCT does not possess the same magnification or contrast as
conventional histopathology, it can visualize tissue microstructure in vivo over a large field
of view and provides real-time, depth-resolved information with micron scale resolution.
Each 3D-OCT dataset in our study covers ∼160 mm2 in the distal esophagus. Although this
is only a fraction of the field observed with white light endoscope it is many times larger
than the field covered by pinch biopsy and 3D-OCT provides complementary information
about BE thickness as well as tissue morphology. This is especially important immediately
after the RFA treatment, when the endoscopic imaging field is covered with blood and tissue
debris. Due to the limited visibility immediately after the RFA treatment, it is difficult to
evaluate the presence of residual glands or unburned BE using white light endoscopy or
NBI. Similarly, imaging modalities that require contrast agents such as confocal
endomicroscopy have limited use since extravasation of the contrast obliterates the viewing
area after RFA. However, as demonstrated, residual glandular structures can be observed
using 3D-OCT.
In this study, 3D-OCT identified structural markers, including the thickness of the BE
epithelium prior to RFA and the presence of residual glands immediately after RFA, which
might be used to predict RFA treatment response at follow-up with high accuracy. We found
that patients with an average BE thickness of over 333 μm were likely to have
endoscopically visible residual BE at the follow-up visit 6-8 weeks after the RFA treatment.
This result was not surprising, however, since the dosage of the RFA treatment has been set
to achieve best efficacy with minimum injury depth.6, 31 The energy delivery of a standard
RFA application might not reach deep enough when the BE epithelium is thick. There are
other possible confounding variables that may contribute to depth variation or
incompleteness of the ablation, including variation of the RFA electrode contact with the
esophagus and coagulated/sloughing debris building up on the electrode surface with
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repeated ablations in a patient.31 Indeed, we found a correlation between the BE epithelium
thickness and the presence of residual glands immediately after RFA, suggesting not all
RFA applications were effective. Insufficient energy delivery at the treatment sites or
leaving BE unburned may be factors that lead to endoscopically visible residual BE at
follow-up.
The efficacy of ablation therapies is generally assessed by follow-up endoscopy 6-8 weeks
after RFA,11-13 and patients undergo repeated ablation if residual BE is observed. Our
results suggest that patient response rate may be stratified based on the BE thickness
measured before RFA. Using this structural marker, it may be possible to adjust RFA
treatment for each patient to optimize response. For patients with thicker BE epithelium, a
more rigorous ablation may be required. This may involve a thorough cleaning of the
ablation catheter and treatment areas to remove debris between the two sets of ablations, and
if indicated, increased dosage for the RFA treatment. The ability of OCT to differentiate
residual glands from normal tissue structures and debris caused by the ablation may also
provide immediate information about the RFA treatment for the endoscopist. This may
enable real-time evaluation of ablation depth and identification of regions requiring further
treatment. The RFA treatment might be guided to further improve the efficacy of each
ablation procedure. As a result, the number of treatment sessions might be reduced to reduce
overall treatment time, patient anxiety and health care cost.
Fourteen non-dysplasia patients were enrolled in the current study. However, RFA treatment
for patients with non-dysplastic BE is still debatable. According to the clinical guidelines for
the management of Barrett's esophagus,32, 33 endoscopic ablation therapies are only
recommended for patients with high-grade dysplasia. Two recent large cohort studies from
Northern Ireland and Denmark showed that the annual risk for adenocarcinoma in non-
dysplastic BE was less than 0.2%, suggesting RFA treatment for patients with non-
dysplastic BE holds no benefit.34, 35 However, an earlier study performed in the U.S.
Veteran population, and perhaps better reflective of this study population, showed a
relatively higher annual risk for adenocarcinoma in non-dysplastic BE patients.36 The
National Cancer Institute estimates that the incidence of esophageal cancer in the general
population of the United States (all races, both sexes, all ages) is approximately 4.5 per
100,000 (0.0045%).37 Hence the incidence of esophageal cancer for patients with non-
dysplastic BE still appears to be much higher than the general population.
Surveillance endoscopy with biopsy is recommended for patients with low-grade dysplasia
or non-dysplastic BE. However, due to the recognized limitations of the surveillance
strategy, such as biopsy sampling errors, lack of compliance with surveillance protocols,
cost-utility considerations, and failure to avert cancer in many cases, endoscopic therapies
intended to completely remove low-grade dysplasia and non-dysplastic BE can be
considered as alternative strategies.9 Indeed, recent studies have shown that complete
eradication of intestinal metaplasia (CE-IM) can be achieved in 92% of patients with non-
dysplastic BE at 5-year follow-up after RFA treatment.9 In this study, the BE epithelial
thickness was found to be a strong predictor for RFA treatment response in all patients with
or without dysplastic BE, indicating that this structural marker can be useful regardless of
the dysplasia status of the patients.
There are several limitations in the current study. First, the study was limited to a cohort of
patients with short-segment BE. This was done because the OCT system had a limited pull
back imaging length and it was desirable to image the GEJ in each data set in order to enable
consistent placement of the OCT imaging catheter. Future OCT systems will be able to
acquire larger data sizes and we plan to extend the study to patients with long segment BE
and evaluate the efficacy of circumferential RFA treatment. The study was also focused on
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patients receiving Halo90 ablation rather than Halo360, to be consistent with the actual
ablation method. In addition, the dysplasia status of the patients was evaluated before the
patients went through the initial RFA treatment. As presented in Table 1, on average 2.4 and
1.7 RFA procedures were performed before the time of OCT imaging for patients in the CE-
IM and non-CE-IM groups, respectively. Biopsies were generally not performed at time of
RFA and OCT imaging to confirm the dysplasia status. Variations in disease severity of the
patients at the time of treatment may be a cofounding variable for treatment response. Future
studies will be conducted to investigate the relation between the BE mucosal thickness and
treatment response in patients with different dysplasia status.
Secondly, the thickness of BE epithelium may vary if the contact pressure of the OCT
catheter on the tissue changes. An ex vivo study using human colon tissues reported that the
epithelium thickness was reduced when the contact pressure is increased.38 This effect may
induce variability in the BE thickness measurement. In the current study, the OCT catheter
was in contact with the esophagus with the endoscope at the neutral position and the
esophagus was deflated during imaging acquisition. The esophagus naturally wrapped
around the OCT catheter to maintain a consistent catheter contact for all patients. More
detailed quantitative investigations are needed to understand the influence of catheter
contact pressure on the BE thickness measurement.
Thirdly, while OCT structural markers may predict RFA treatment response, the current
study does not address whether the RFA treatment efficacy can be improved and the number
of treatments reduced using structural information provided by 3D-OCT. A rigorous
longitudinal study is needed to further establish the utility of endoscopic 3D-OCT for
guiding RFA treatment of BE in clinical practice.
Finally, although the imaging coverage of the current 3D-OCT catheter is significantly
larger than standard biopsy, a single 3D-OCT scan only covered about one sixth of the
circumference of the distal esophagus. If unburned BE or residual glands were missed by
3D-OCT immediately after RFA, the patient might fail to achieve CE-IM at follow-up even
though OCT imaging may still predict complete response. To overcome these potential
sampling errors, multiple 3D-OCT sets will need to be acquired to achieve comprehensive
coverage over different quadrants of the distal esophagus. Other OCT probe designs, such as
balloon probes, may also be employed to improve coverage and reduce potential sampling
errors in the future.
Conclusion
Endoscopic 3D-OCT can identify structural markers, including the thickness of the BE
epithelium prior to RFA and the presence of residual glands immediately after RFA. These
markers are promising predictors of RFA treatment response at follow up in patients with
short-segment BE. 3D-OCT may provide valuable information which will enable
endoscopists to make real-time treatment decisions improving the efficacy of RFA treatment
and reducing the number of required treatments in the future.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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AUC area under the curve
BE Barrett's esophagus
CE complete eradication
CE-D complete eradication of dysplasia




HGD high grade dysplasia
IM intestinal metaplasia
LGD low grade dysplasia
LP lamina propria
MM muscularis mucosa
NBI narrow band imaging
NDBE non-dysplastic Barrett's esophagus
NPV negative predicting value
OCT optical coherence tomography
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PPI proton pump inhibitor
PPV positive predicting value
RFA radiofrequency ablation
ROC receiver operator characteristic
SD standard deviation
VABHS Veterans Affairs Boston Healthcare System
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Thicker BE epithelium measured by 3D-OCT prior to ablation is associated with reduced
treatment response of RFA assess at follow up. The presence of residual glands
immediately after RFA is also correlated with thicker BE prior to RFA as well as with
treatment response at follow up. 3D-OCT provides a useful tool for for identifying
factors are associated with RFA treatment response and may improve the effectiveness of
therapy to reduce the number of treatments required to achieve complete response in the
future.
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(A) Representative endoscopic image of the GEJ before RFA treatment. (B) Representative
cross-sectional OCT image and (C) corresponding histology illustrating the BE epithelium
thickness measurement.
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(A) Representative endoscopic image of the GEJ immediately after RFA treatment. (B)
Representative cross-sectional OCT image showing unburned BE epithelium missed by
RFA. (C) Representative cross-sectional OCT image showing residual glands after RFA. (D)
Corresponding histology of (C) confirming residual BE glands after RFA. (E)
Representative cross-sectional OCT image showing effective RFA treatment. The entire BE
epithelium was ablated, resulting in exposed muscularis mucosa (MM) on the surface.
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(A) Scatter plot of the average BE epithelium thickness measured by OCT. Blue circles:
Non-CE-IM group; Red crosses: CE-IM group; Green dotted line: discrimination threshold
at 333 μm as determined from the average BE thickness ROC curve in (B). (B) ROC curves
of treatment response prediction using average (green) and maximum (blue) BE thickness.
The area-under-the-curve (AUC) values were 0.942 (p<0.001) and 0.934 (p<0.001) using
the average and maximum BE thickness, respectively.
Tsai et al. Page 16







Tsai et al. Page 17
Table 1
Subject demographic information
CE-IM Group Non-CE-IM Group P Value
Enrollment 13 20
Gender, male/female 12/1 20/0
Race 13 Caucasian 20 Caucasian
Age [years]
 Mean (SD) 64.9 (7.7) 65.6 (15.8) 0.86
 Range 51-77 33-92
Initial Diagnosis
 BE w/o dysplasia 4 10
 LGD 2 4
 HGD 7 6
Prior RFA Treatments
 Mean (SD) 2.4 (1.9) 1.7 (1.6) 0.34
 Range 0-7 0-6
Length of BE [cm]
 Mean (SD) 1.3 (0.8) 1.0 (0.7) 0.29
 Range 0.5-3 0.5-3
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Table 2
Average BE thickness measured by OCT before RFA predicts the presence or absence of
endoscopically visible residual BE at follow-up visit
Absence of Residual BE at
Follow-up
Presence of Residual BE at
Follow-up
Total
Average BE Thickness <
333 μm
12 3 15 PPV = 80%
Average BE Thickness ≥
333 μm
1 17 18 NPV = 94.4%
Total 13 20 33
Sensitivity = 92.3% Specificity = 85% Accuracy = 87.9%
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Table 3
Average BE thickness measured by OCT before RFA predicts the presence or absence of
residual glands measured by OCT immediately after RFA
Absence of Residual Glands
Immediately after RFA
Presence of Residual Glands
Immediately after RFA
Total
Average BE Thickness <
333 μm
11 3 14 PPV = 78.6%
Average BE Thickness ≥
333 μm
1 17 18 NPV = 94.4%
Total 12 20 32
Sensitivity = 91.7% Specificity = 85% Accuracy = 87.5%
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Table 4
Presence or absence of residual glands measured by OCT immediately after RFA predicts
the presence or absence of endoscopically visible residual BE at follow-up visit
Absence of Residual BE at
Follow-up
Presence of Residual BE at
Follow-up
Total
Absence of Residual Glands
Immediately after RFA
10 1 11 PPV = 90.9%
Presence of Residual Glands
Immediately after RFA
2 19 21 NPV = 90.5%
Total 12 20 32
Sensitivity = 83.3% Specificity = 95% Accuracy = 90.6%
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